Literature DB >> 19608640

Sentinel lymph node biopsy in the management of vulvar carcinoma, cervical cancer, and endometrial cancer.

Oliver Zivanovic1, Fady Khoury-Collado, Nadeem R Abu-Rustum, Mary L Gemignani.   

Abstract

The treatment of gynecologic malignancies can include surgery, systemic therapy, and radiation. Depending on the primary site of disease and the extent of the disease, these treatment strategies are applied alone or in combination. Trends over the past few decades have concentrated on performing more comprehensive staging procedures for a large percentage of patients with gynecologic malignancies. The surgical techniques available for comprehensive staging have facilitated a greater understanding of stage and prognosis overall, and better tailoring of postsurgical treatment. One such technique is regional lymphadenectomy. Although the role of regional lymphadenectomy as a therapeutic procedure in some gynecologic cancers is debated and challenged (regional lymphadenectomy and multimodality therapy increases adverse side effects and long-term sequelae without proven survival benefit), there is no controversy regarding the staging and prognostic benefit of the evaluation of regional lymph nodes. The sentinel lymph node (SLN) concept was successfully introduced in melanoma. It has since become the standard of care in breast cancer and has had a significant impact on postoperative morbidity for a large percentage of breast cancer patients. Interest in using SLN techniques in gynecologic cancers was thus a natural progression. In light of the growing body of evidence in the literature opposing the therapeutic benefit of systematic lymphadenectomy, the SLN concept will continue to play an important role in the treatment of gynecologic malignancies. This technique can provide accurate staging information in some gynecologic cancers. Increased use of this technique could potentially impact the quality of life of gynecologic cancer survivors while still providing important staging information without compromising oncologic safety. In this review, we examine the body of literature related to gynecologic cancer malignancies and SLN biopsy.

Entities:  

Mesh:

Year:  2009        PMID: 19608640     DOI: 10.1634/theoncologist.2009-0075

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  11 in total

1.  Multispectral real-time fluorescence imaging for intraoperative detection of the sentinel lymph node in gynecologic oncology.

Authors:  Lucia M A Crane; George Themelis; K Tim Buddingh; Tim Buddingh; Niels J Harlaar; Rick G Pleijhuis; Athanasios Sarantopoulos; Ate G J van der Zee; Vasilis Ntziachristos; Gooitzen M van Dam
Journal:  J Vis Exp       Date:  2010-10-20       Impact factor: 1.355

Review 2.  Contemporary quality of life issues affecting gynecologic cancer survivors.

Authors:  Jeanne Carter; Richard Penson; Richard Barakat; Lari Wenzel
Journal:  Hematol Oncol Clin North Am       Date:  2011-12-16       Impact factor: 3.722

Review 3.  Update on sentinel lymph node evaluation in gynecologic malignancies.

Authors:  Katina Robison; Laura L Holman; Richard G Moore
Journal:  Curr Opin Obstet Gynecol       Date:  2011-02       Impact factor: 1.927

4.  Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping.

Authors:  Maria B Schiavone; Chiara Scelzo; Celeste Straight; Qin Zhou; Kaled M Alektiar; Vicky Makker; Robert A Soslow; Alexia Iasonos; Mario M Leitao; Nadeem R Abu-Rustum
Journal:  Ann Surg Oncol       Date:  2017-03-03       Impact factor: 5.344

Review 5.  [Metastatic mechanisms of uterine malignancies and therapeutic consequences].

Authors:  S F Lax; K F Tamussino; P F Lang
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

6.  Sentinel lymph node mapping using indocyanine green in patients with uterine and cervical neoplasms: restrictions of the method.

Authors:  M Bedyńska; G Szewczyk; T Klepacka; K Sachadel; T Maciejewski; D Szukiewicz; A Fijałkowska
Journal:  Arch Gynecol Obstet       Date:  2019-02-14       Impact factor: 2.344

7.  Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis.

Authors:  Alvin Gogineni; Maresa Caunt; Ailey Crow; Chingwei V Lee; Germaine Fuh; Nicholas van Bruggen; Weilan Ye; Robby M Weimer
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

Review 8.  Emotional and sexual concerns in women undergoing pelvic surgery and associated treatment for gynecologic cancer.

Authors:  Cara Stabile; Abigail Gunn; Yukio Sonoda; Jeanne Carter
Journal:  Transl Androl Urol       Date:  2015-04

9.  Sentinel lymph node mapping in gynecological oncology.

Authors:  Jiang Du; Yaling Li; Qing Wang; Nasra Batchu; Junkai Zou; Chao Sun; Shulan Lv; Qing Song; Qiling Li
Journal:  Oncol Lett       Date:  2017-10-18       Impact factor: 2.967

10.  Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer.

Authors:  Toshiaki Saito; Tsutomu Tabata; Hitoshi Ikushima; Hiroyuki Yanai; Hironori Tashiro; Hitoshi Niikura; Takeo Minaguchi; Toshinari Muramatsu; Tsukasa Baba; Wataru Yamagami; Kazuya Ariyoshi; Kimio Ushijima; Mikio Mikami; Satoru Nagase; Masanori Kaneuchi; Nobuo Yaegashi; Yasuhiro Udagawa; Hidetaka Katabuchi
Journal:  Int J Clin Oncol       Date:  2017-11-20       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.